FDA's Henney Will Need To Tackle FY 2000 Budget To Address Staffing Levels
This article was originally published in The Gray Sheet
Executive SummaryOne of the first major challenges facing FDA Commissioner Jane Henney will be the development of an agency budget for fiscal year 2000 that addresses what officials call a "growing shortfall" of resources.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.